null

Phospho-ESRalpha-S118 Antibody (CABP0146)

SKU:
CABP0146
Product Type:
Antibody
Applications:
WB
IHC
IF
Reactivity:
Human
Host Species:
Rabbit
Isotype:
IgG
Research Area:
Epigenetics and Nuclear Signaling
  • Epigenetics and Nuclear Signaling Antibodies 4 Anti-Phospho-Estrogen receptor-S118 Antibody CABP0146
  • Epigenetics and Nuclear Signaling Antibodies 4 Anti-Phospho-Estrogen receptor-S118 Antibody CABP0146
  • Epigenetics and Nuclear Signaling Antibodies 4 Anti-Phospho-Estrogen receptor-S118 Antibody CABP0146
$191 - $503
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

Phospho-ESRα-S118 Rabbit Polyclonal Antibody (CABP0146)

The Phospho-Estrogen Receptor S118 Polyclonal Antibody (CABP0146) is a valuable tool for researchers studying estrogen receptor signaling pathways. This antibody, raised in rabbits, is highly specific and reactive with human samples, making it ideal for Western blot applications. By binding to the phosphorylated form of the Estrogen Receptor at Serine 118, this antibody enables researchers to detect and analyze the activation of this critical signaling molecule in various cell types.The Estrogen Receptor is a nuclear receptor that plays a key role in regulating gene expression in response to estrogen. Phosphorylation of the Estrogen Receptor at Serine 118 is known to enhance its transcriptional activity, influencing the expression of genes involved in cell proliferation, differentiation, and survival.

Understanding the phosphorylation status of the Estrogen Receptor is essential for unraveling the complex mechanisms of estrogen signaling in normal physiology and diseases like breast cancer.By using the Phospho-Estrogen Receptor S118 Polyclonal Antibody, researchers can gain valuable insights into the activation and regulation of the Estrogen Receptor in cellular processes. This antibody is a valuable tool for studies in cancer biology, endocrinology, and hormone-related disorders, paving the way for the development of targeted therapies and personalized treatments in the future.